ArticleCardio-oncology (London, England)2025
Cardiotoxicity of combined pegylated liposomal doxorubicin and bevacizumab therapy: a propensity-matched cohort study and disproportionality analysis.
Article in Cardio-oncology (London, England), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Real-world adverse event profile and signal characteristics of bevacizumab in glioma: a FAERS-based disproportionality analysis.Frontiers in pharmacology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPegylated liposomal doxorubicin (PLD) and bevacizumab are commonly used to treat platinum-resistant ovarian cancer. While both agents are associated with cardiovascular toxicities, their combined impact on cardiotoxicity in real-world settings is not well defined. This study investigates whether co-administration of PLD and bevacizumab increases the risk of cardiovascular adverse events compared to PLD alone.
methodsA retrospective cohort study was conducted using the TriNetX Analytics Network Database. Patients treated with PLD and bevacizumab were matched 1:1 to those receiving PLD alone using propensity score matching. Cardiovascular outcomes, including heart failure, cardiomyopathy, hypertension, and venous thromboembolism, were assessed over two years. Replication was performed using VigiBase, the World Health Organization’s global adverse drug reaction database, through disproportionality analysis.
resultsAmong 1,194 matched patients in each group, combination therapy was associated with increased risks of heart failure or cardiomyopathy (OR 1.42, 95% CI 1.07–1.88, P = 0.015), hypertension (OR 1.80, 95% CI 1.36–2.38, P < 0.001), venous thromboembolism (OR 1.23, 95% CI 1.02–1.49, P = 0.029), and all-cause mortality (OR 1.26, 95% CI 1.07–1.48, P = 0.005). VigiBase analysis confirmed disproportionate reporting of hypertension (ROR 6.05, 95% CI 4.61–7.94), heart failure (ROR 1.75, 95% CI 1.23–2.47), and pericardial disorders (ROR 3.67, 95% CI 1.61–8.38) in patients receiving combination therapy.
conclusionsCombined PLD and bevacizumab therapy was associated with increased risk of cardiotoxicity compared to PLD alone. These findings emphasize the need for proactive cardiovascular monitoring in patients undergoing this combination treatment. Prospective studies are warranted to further elucidate the underlying mechanisms and to refine clinical management strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.